异基因造血干细胞移植治疗恶性血液病的预后分析 |
| |
引用本文: | 宁丰,王景文,杨磊,崔晶,栗宇,李鑫,尹秀秀. 异基因造血干细胞移植治疗恶性血液病的预后分析[J]. 白血病.淋巴瘤, 2009, 19(10): 338-340. DOI: 10.3760/cma.j.issn.1009-9921.2010.06.006 |
| |
作者姓名: | 宁丰 王景文 杨磊 崔晶 栗宇 李鑫 尹秀秀 |
| |
作者单位: | 首都医科大学附属北京同仁医院血液内科,100730; |
| |
摘 要: | Objective To explore the clinical related prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating malignant hematological diseases. Methods From September 1997 to August 2008,a total of 26 patients with hematological diseases were treated with allo-HSCT from HLA identical-sibling and haplo-identical donors in our hospital, including 14 patients with acute leukemias,10 with chronic myeloid leukemias,and 2 myelodysplastic syndromes. Results All patients achieved sustained full donor type engraftment. The cumulative overall survival (OS) was 63.9 %,and cumulative disease free survival (DFS) was 62.6 %. Fifteen patients had graft-versus-host disease (GVHD) (57.7 %),including 8 acute GVHD(aGVHD) (30.8 %) (grade Ⅲ-Ⅳ aGVHD was 15.4 %) and 7 chronic GVHD. GVHD between HLA identical-sibling and haplo-identical donors was different and there was statistic difference between the two groups (P=0.014). 4 patients relapsed,7 patients died. The univariate analysis showed OS were correlated with grade Ⅳ aGVHD (P=0.05) and CMV infection (P=0.027). Conclusion Allo-HSCT is effective for the cure of patients with malignant hematological diseases. The key to improve the efficacy of HSCT is to reduce the incidence of transplant-related complications,especially GVHD and infection.
|
关 键 词: | 血液肿瘤 造血干细胞移植 移植,同种 预后 |
Prognostic analysis of allogeneic hematopoietic stem cell transplantation in treating patients with malignant hematological diseases |
| |
Abstract: | |
| |
Keywords: | Hematological neoplasmsHematopoietic stem cell transplantationTransplantation homologusPrognosis |
|
|